Pranoprofen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pranoprofen
Accession Number
DB13514
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
2R7O1ET613
CAS number
52549-17-4
Weight
Average: 255.2686
Monoisotopic: 255.089543287
Chemical Formula
C15H13NO3
InChI Key
TVQZAMVBTVNYLA-UHFFFAOYSA-N
InChI
InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)
IUPAC Name
2-{5H-chromeno[2,3-b]pyridin-7-yl}propanoic acid
SMILES
CC(C(O)=O)C1=CC2=C(OC3=C(C2)C=CC=N3)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with (S)-Warfarin.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pranoprofen is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with 4-hydroxycoumarin.
AbacavirPranoprofen may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Abciximab.
AcarbosePranoprofen may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcebutololPranoprofen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pranoprofen.
AcemetacinThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Acemetacin.
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041996
ChemSpider
4719
BindingDB
50286819
ChEBI
32040
ChEMBL
CHEMBL367463
Wikipedia
Pranoprofen
ATC Codes
S01BC09 — Pranoprofen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentRetinal Diseases1
Not AvailableRecruitingNot AvailableKeratitis, Herpetic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.03 mg/mLALOGPS
logP2.54ALOGPS
logP2.94ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)3.63ChemAxon
pKa (Strongest Basic)2.24ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.42 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity70.02 m3·mol-1ChemAxon
Polarizability26.86 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-1290000000-d70f1e7dd20d79171ae0

Taxonomy

Description
This compound belongs to the class of organic compounds known as chromeno[2,3-b]pyridines. These are aromatic heteropolycyclic compounds containing pyridine linearly fused to the pyran moiety of a benzofuran ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrans
Sub Class
1-benzopyrans
Direct Parent
Chromeno[2,3-b]pyridines
Alternative Parents
Diarylethers / Pyranopyridines / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Chromeno[2,3-b]pyridine / Diaryl ether / Pyranopyridine / Pyridine / Benzenoid / Heteroaromatic compound / Carboxylic acid derivative / Carboxylic acid / Ether / Monocarboxylic acid or derivatives
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:43 / Updated on November 02, 2018 07:41